Precision Therapeutics (NASDAQ:POAI) Shares Up 7.1%

Precision Therapeutics Inc (NASDAQ:POAI) shares shot up 7.1% during trading on Friday . The stock traded as high as $3.95 and last traded at $3.48, 126,100 shares traded hands during trading. An increase of 175% from the average session volume of 45,930 shares. The stock had previously closed at $3.25.

Separately, ValuEngine raised Precision Therapeutics from a “hold” rating to a “buy” rating in a report on Tuesday, December 3rd.

The company has a quick ratio of 0.08, a current ratio of 0.10 and a debt-to-equity ratio of 0.02. The stock has a fifty day moving average price of $2.81.

Precision Therapeutics (NASDAQ:POAI) last announced its quarterly earnings data on Friday, November 15th. The medical instruments supplier reported ($1.31) earnings per share (EPS) for the quarter. The business had revenue of $0.52 million during the quarter. Precision Therapeutics had a negative net margin of 674.64% and a negative return on equity of 86.24%.

An institutional investor recently bought a new position in Precision Therapeutics stock. Vanguard Group Inc. acquired a new stake in Precision Therapeutics Inc (NASDAQ:POAI) during the second quarter, according to its most recent Form 13F filing with the SEC. The fund acquired 155,934 shares of the medical instruments supplier’s stock, valued at approximately $115,000. Vanguard Group Inc. owned 0.51% of Precision Therapeutics at the end of the most recent reporting period. Institutional investors and hedge funds own 10.78% of the company’s stock.

Precision Therapeutics Company Profile (NASDAQ:POAI)

Predictive Oncology Inc provides various healthcare products and services primarily in the United States. The company manufactures environmentally conscious systems for the collection and disposal of infectious fluids that result from surgical procedures and post-operative care. It offers the STREAMWAY Fluid Waste Management system that suctions surgical waste fluid from the patient using standard surgical tubing; and disposables.

Further Reading: Guidelines for Successful Channel Trading

Receive News & Ratings for Precision Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Precision Therapeutics and related companies with's FREE daily email newsletter.